Jiangsu Nanfang Medical
Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal, medical proof fabrics, adhesive tapes and bandages, sports protection, first-aid kits, and care products in China and internationally. It offers medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical … Read more
Jiangsu Nanfang Medical (603880) - Net Assets
Latest net assets as of September 2025: CN¥259.57 Million CNY
Based on the latest financial reports, Jiangsu Nanfang Medical (603880) has net assets worth CN¥259.57 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥993.46 Million) and total liabilities (CN¥733.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥259.57 Million |
| % of Total Assets | 26.13% |
| Annual Growth Rate | 7.35% |
| 5-Year Change | -59.42% |
| 10-Year Change | 27.82% |
| Growth Volatility | 35.78 |
Jiangsu Nanfang Medical - Net Assets Trend (2012–2024)
This chart illustrates how Jiangsu Nanfang Medical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jiangsu Nanfang Medical (2012–2024)
The table below shows the annual net assets of Jiangsu Nanfang Medical from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥284.41 Million | -40.03% |
| 2023-12-31 | CN¥474.22 Million | -23.70% |
| 2022-12-31 | CN¥621.48 Million | -5.10% |
| 2021-12-31 | CN¥654.90 Million | -6.55% |
| 2020-12-31 | CN¥700.80 Million | +23.48% |
| 2019-12-31 | CN¥567.52 Million | +1.34% |
| 2018-12-31 | CN¥560.04 Million | +4.18% |
| 2017-12-31 | CN¥537.57 Million | +109.43% |
| 2016-12-31 | CN¥256.69 Million | +15.36% |
| 2015-12-31 | CN¥222.51 Million | +5.50% |
| 2014-12-31 | CN¥210.90 Million | +25.11% |
| 2013-12-31 | CN¥168.57 Million | +38.88% |
| 2012-12-31 | CN¥121.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Nanfang Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1140.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥289.04 Million | 103.49% |
| Other Comprehensive Income | CN¥42.23 Million | 15.12% |
| Other Components | CN¥106.24 Million | 38.04% |
| Total Equity | CN¥279.29 Million | 100.00% |
Jiangsu Nanfang Medical Competitors by Market Cap
The table below lists competitors of Jiangsu Nanfang Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FAP Agri Tbk PT
JK:FAPA
|
$137.79 Million |
|
West Red Lake Gold Mines Ltd.
OTCGREY:WRLGF
|
$137.79 Million |
|
United Security Bancshares
NASDAQ:UBFO
|
$137.80 Million |
|
Kelly Partners Group Holdings Limited
OTCQX:KPGHF
|
$137.81 Million |
|
China Fangda Group Co Ltd
SHE:200055
|
$137.75 Million |
|
Golden Flower Tbk PT
JK:POLU
|
$137.61 Million |
|
Gaotu Techedu Inc
F:18WA
|
$137.59 Million |
|
Sarawak Oil Palms Bhd
KLSE:5126
|
$137.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Nanfang Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 469,268,077 to 279,286,644, a change of -189,981,433 (-40.5%).
- Net loss of 190,668,979 reduced equity.
- Dividend payments of 27,079,802 reduced retained earnings.
- Share repurchases of 18,601,440 reduced equity.
- Other comprehensive income increased equity by 41,866,199.
- Other factors increased equity by 4,502,589.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-190.67 Million | -68.27% |
| Dividends Paid | CN¥27.08 Million | -9.7% |
| Share Repurchases | CN¥18.60 Million | -6.66% |
| Other Comprehensive Income | CN¥41.87 Million | +14.99% |
| Other Changes | CN¥4.50 Million | +1.61% |
| Total Change | CN¥- | -40.48% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Nanfang Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.89x to 7.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.57 | CN¥7.35 | x |
| 2013-12-31 | CN¥0.79 | CN¥7.35 | x |
| 2014-12-31 | CN¥0.98 | CN¥7.35 | x |
| 2015-12-31 | CN¥1.03 | CN¥7.35 | x |
| 2016-12-31 | CN¥1.18 | CN¥7.35 | x |
| 2017-12-31 | CN¥2.24 | CN¥7.35 | x |
| 2018-12-31 | CN¥1.93 | CN¥7.35 | x |
| 2019-12-31 | CN¥1.98 | CN¥7.35 | x |
| 2020-12-31 | CN¥2.38 | CN¥7.35 | x |
| 2021-12-31 | CN¥2.22 | CN¥7.35 | x |
| 2022-12-31 | CN¥2.13 | CN¥7.35 | x |
| 2023-12-31 | CN¥1.62 | CN¥7.35 | x |
| 2024-12-31 | CN¥0.97 | CN¥7.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Nanfang Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.64%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 3.78x
- Recent ROE (-68.27%) is below the historical average (4.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 29.47% | 8.42% | 1.12x | 3.13x | CN¥23.63 Million |
| 2013 | 28.50% | 9.41% | 1.37x | 2.21x | CN¥31.19 Million |
| 2014 | 25.48% | 11.36% | 1.08x | 2.09x | CN¥32.43 Million |
| 2015 | 23.20% | 11.83% | 0.91x | 2.14x | CN¥29.16 Million |
| 2016 | 20.55% | 11.70% | 0.86x | 2.04x | CN¥26.68 Million |
| 2017 | 8.95% | 9.74% | 0.59x | 1.55x | CN¥-5.58 Million |
| 2018 | 7.05% | 8.18% | 0.57x | 1.52x | CN¥-16.42 Million |
| 2019 | 4.97% | 5.71% | 0.57x | 1.54x | CN¥-28.36 Million |
| 2020 | 14.07% | 9.14% | 1.00x | 1.54x | CN¥28.39 Million |
| 2021 | -3.55% | -4.37% | 0.43x | 1.90x | CN¥-88.02 Million |
| 2022 | -2.42% | -2.74% | 0.37x | 2.36x | CN¥-76.60 Million |
| 2023 | -31.41% | -24.57% | 0.47x | 2.72x | CN¥-194.34 Million |
| 2024 | -68.27% | -31.64% | 0.57x | 3.78x | CN¥-218.60 Million |
Industry Comparison
This section compares Jiangsu Nanfang Medical's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,246,530,775
- Average return on equity (ROE) among peers: 12.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Nanfang Medical (603880) | CN¥259.57 Million | 29.47% | 2.83x | $137.76 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $234.74 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $784.88 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.62 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |